Korro Bio, Inc. (KRRO)
12.17
+0.55
(+4.73%)
USD |
NASDAQ |
Sep 04, 12:26
Korro Bio Shareholders Equity (Quarterly) : 103.23M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 103.23M |
| March 31, 2026 | 119.63M |
| December 31, 2025 | 51.44M |
| September 30, 2025 | 99.03M |
| June 30, 2025 | 115.10M |
| March 31, 2025 | 138.96M |
| December 31, 2024 | 160.42M |
| September 30, 2024 | 179.63M |
| June 30, 2024 | 198.08M |
| March 31, 2024 | 151.36M |
| December 31, 2023 | 169.91M |
| September 30, 2023 | 36.74M |
| June 30, 2023 | 45.41M |
| March 31, 2023 | 53.25M |
| Date | Value |
|---|---|
| December 31, 2022 | -99.03M |
| September 30, 2022 | 81.97M |
| June 30, 2022 | 95.85M |
| March 31, 2022 | 112.67M |
| December 31, 2021 | 130.82M |
| September 30, 2021 | 147.12M |
| June 30, 2021 | 166.04M |
| March 31, 2021 | 177.41M |
| December 31, 2020 | 192.49M |
| September 30, 2020 | 199.59M |
| June 30, 2020 | 161.70M |
| March 31, 2020 | 164.85M |
| December 31, 2019 | 167.36M |
| September 30, 2019 | -59.65M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 163.45M |
| Total Liabilities (Quarterly) | 60.22M |
| Debt to Equity Ratio | 0.4089 |
| Current Ratio | 9.553 |
| Net Debt Paydown Yield | 0.31% |